WATERTOWN, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of ...

Human brain health research is moving beyond universal “norms” toward models that treat culture, language, environment, and structural conditions as central ...

Vigil Neuroscience, Inc. has announced its financial results for Q1 2025 and provided updates on its clinical trials. The company is on track to report the final analysis from its Phase 2 IGNITE trial ...

- Safety, tolerability, pharmacokinetic, and pharmacodynamic profile supports continued development of VG-3927 as potential once-daily oral therapy for Alzheimer’s disease (AD) - - Robust and ...

JUPITER, FL, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company focused on neuroinflammation and central ...

HELUS Pharma has rebranded and moved to Nasdaq, signaling a shift toward late-stage clinical development and commercial focus. Key 2026 catalysts include Phase 3 data for HLP003 in major depressive ...

Axon Neuroscience’s active tau immunotherapy AADvac1 has been selected as the first tau-targeted therapy to enter a groundbreaking U.S. Alzheimer’s disease phase 2 clinical trial (supported by a USD ...

Researchers identify specific immune markers, like activated monocytes and cytokines, that drive cognitive decline after viral infections across various diseases.

JUPITER, FL, UNITED STATES, February 25, 2026 /EINPresswire.com/ — Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage ...